Form 4: Medpace President Sells 21,503 Shares

Medpace Holdings, Inc. President Jesse J. Geiger sold 21,503 shares of common stock at a weighted average price of $595.66 per share under a pre-arranged 10b5-1 plan.

Summary

• Jesse J. Geiger, President of Medpace Holdings, Inc., disposed of 21,503 shares of common stock.
• The transaction occurred on November 5, 2025.
• The shares were sold at a weighted average price of $595.66 per share, with individual transactions ranging from $588.64 to $599.86.
• Following the sale, Geiger beneficially owns 15,000 shares directly.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted on August 6, 2025.

Sentiment

Score: 5

Explanation: A neutral score, as the insider sale is pre-planned under a 10b5-1 plan, which mitigates the negative signal typically associated with insider selling. It's a routine personal financial management event rather than a reflection of company performance or outlook.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating it was not based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the direct ownership stake of a key executive.

Risks

• Potential investor perception of reduced insider confidence, despite the 10b5-1 plan.

Future Outlook

No specific future outlook or guidance was provided in this Form 4 filing, which primarily reports a past transaction.

Industry Context

This Form 4 filing reports a routine insider transaction for an executive at a contract research organization (CRO). Such transactions are common for executives managing personal finances and are often pre-scheduled, as indicated by the 10b5-1 plan, which helps to mitigate concerns about trading on material non-public information.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May perceive a slight negative signal due to reduced insider ownership, though the 10b5-1 plan lessens this impact.

Next Steps

• No specific future actions or milestones were mentioned in this Form 4 filing.

Key Dates

Recommendation

The filing reports a routine, pre-planned insider sale by an executive under a Rule 10b5-1 plan. While it reduces insider ownership, the pre-scheduled nature suggests it's for personal financial management rather than a reflection of new negative company information. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, warranting a 'hold' based solely on this filing.

Keywords

Medpace Holdings, MEDP, Insider Trading, Form 4, Stock Sale, Jesse J. Geiger, 10b5-1 Plan, Executive Compensation